Farcast Biosciences develops the Farcast Human Tumor Microdynamics Platform, which generates multimodal data to model tumor response and resistance to therapies using true-to-human biological systems. This technology enables researchers to identify effective treatment regimens and predict patient responses with greater accuracy, addressing the challenge of personalized cancer therapy.
Funding
$120K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Predicting patient response to cancer therapies remains a significant challenge due to the complex interactions within the tumor microenvironment and the limitations of traditional preclinical models. Current methods often fail to capture the heterogeneity of tumors and the dynamic interplay between tumor, stromal, and immune components, leading to inaccurate predictions of treatment efficacy.
Solution
Farcast Biosciences offers the Farcast Human Tumor Microdynamics Platform, an advanced biological system that preserves the native contexture of the human tumor microenvironment to model tumor response and resistance to various therapies. The platform utilizes living, near-native, heterogeneous tumor systems to enable simultaneous interrogation of multiple therapies, including combinations, across all therapy classes. By generating high-quality, multimodal data through orthogonal assays, the platform captures a wide range of response and resistance signals, providing actionable insights for therapeutic development and diagnostics. The platform's AI capabilities mine this data to discover biosignatures with higher predictive power compared to simplistic biomarkers, facilitating more precise identification of responder phenotypes.
Target Audience
The primary target audience includes biopharmaceutical companies involved in drug development and diagnostic companies seeking to improve patient selection for cancer therapies.
Features
- TruTumor: Advanced systems for generating true-to-human, multimodal tumor microdynamics data.
- TruNet: Network of global cancer centers for processing multi-population tumor samples.
- Ability to integrate a wide range of response and resistance signals by maintaining the equilibrium between stromal, tumor, and immune components.
- Simultaneous interrogation of multiple therapies and combinations.
- Compatibility with all therapy classes, including bi-specifics, monoclonal antibodies, immune checkpoint inhibitors, and small molecules.
- Integrated multi-dimensional readouts, including histopathology, gene expression, spatial biology, flow cytometry, cytokine profiling, and kinetic assays.
- AI-enabled technology for computing response biosignatures with higher precision.